Santos F N, Borja-Cabrera G P, Miyashiro L M, Grechi J, Reis A B, Moreira M A B, Martins Filho O A, Luvizotto M C R, Menz I, Pessôa L M, Gonçalves P R, Palatnik M, Palatnik-de-Sousa C B
Instituto de Microbiologia Prof. Paulo de Góes, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, PO Box 68040, CEP 21941-590, Rio de Janeiro, Brasil.
Vaccine. 2007 Aug 14;25(33):6176-90. doi: 10.1016/j.vaccine.2007.06.005. Epub 2007 Jun 21.
In order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune vaccine, formulated with an increased adjuvant concentration (1mg of saponin rather than 0.5mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi. The enriched-Leishmune vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune-treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p<0.0001), a higher and stable IgG2 and a decreasing IgG1 response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania-specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93-49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune immunotherapy-treated dogs (15.75, CI95% 13.97-17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p<0.0001), the parasitological evidence (p=0.038) and a decrease in Leishmania-specific CD4+ lymphocyte proportions (p=0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog's potential infectiosity to phlebotomines. The enriched-Leishmune vaccine was subjected to a safety analysis and found to be well tolerated and safe.
为了评估佐剂浓度增加(1毫克皂苷而非0.5毫克)的Leishmune疫苗对犬内脏利什曼病的免疫治疗潜力,24只杂种犬感染了恰加斯利什曼原虫(Leishmania (L.) chagasi)。在感染后的第6、7和8个月,当动物出现血清阳性且有症状时,注射强化的Leishmune疫苗。对照组注射生理盐水。接受Leishmune治疗的犬显示出抗FML IgG抗体水平显著更高(方差分析;p<0.0001),IgG2更高且稳定,IgG1反应降低,表明是由TH1 T细胞介导的反应。该疫苗有以下效果:与对照组(50%)相比,接种疫苗的犬对利什曼原虫裂解物的迟发型超敏反应阳性率更高(75%);生理盐水对照组中CD4 +利什曼原虫特异性淋巴细胞的平均比例降低(32.13%),超出了接种疫苗犬的95%置信区间(41.62%,CI95% 43.93 - 49.80);生理盐水对照组的临床评分平均值增加(17.83),超出了接受Leishmune免疫治疗犬的95%置信区间(15.75,CI95% 13.97 - 17.53)。所有接受疫苗的犬聚集在一起,临床评分较低且CD4 +计数正常,而42%未治疗的犬CD4 +显著减少且临床评分更高。生理盐水治疗组临床症状的增加与抗FML抗体的增加(p<0.0001)、寄生虫学证据(p = 0.038)以及利什曼原虫特异性CD4 +淋巴细胞比例的降低(p = 0.035)相关。这些结果证实了强化Leishmune疫苗的免疫治疗潜力。该疫苗减轻了临床症状和寄生虫证据,调节了感染结果以及犬对白蛉的潜在传染性。对强化Leishmune疫苗进行了安全性分析,发现其耐受性良好且安全。